Carisma Therapeutics

Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors

Add To Watchlist
General Information
Company Name
Carisma Therapeutics
Founded Year
2016
Location (Offices)
Philadelphia, United States +1
Founders / Decision Makers
Steven Kelly - President & Chief Executive Officer Tom Wilton - CBO Daniel Cushing - CTO & CDO Michael Klichinsky - Co-Founder and Chief Scientific Officer Kenneth Locke - VP, Manufacturing
Number of Employees
80
Industries
Biotechnology, Health Care, Health and Wellness +1
Funding Stage
Series C
Social Media

Carisma Therapeutics - Company Profile

Carisma Therapeutics is a clinical stage biopharmaceutical company founded in 2016 and headquartered in Philadelphia, PA. The company focuses on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies for cancer and other serious diseases. Carisma has created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Their slogan, "Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors", encapsulates their innovative approach to treating solid tumors.

In their last Series C investment round on 21 September 2022, Carisma Therapeutics secured $30.00M, drawing investment from a diverse group of backers including HealthCap, Wellington Partners, Agent Capital, MRL Ventures Fund, Solasta Ventures, Symbiosis LLC, TPG Biotech, Pictet Alternative Advisors, Penn Medicine Co-Investment Program, and Livzon Pharmaceutical Group.

The company operates in the Biotechnology, Health Care, Health and Wellness, and Life Sciences industries, positioning itself at the intersection of healthcare and technology to address unmet medical needs with innovative solutions. With its strong investor backing and innovative approach, Carisma Therapeutics is poised to make strides in the field of immunotherapy and cancer treatment.

Taxonomy: biopharmaceutical company, cell therapy platform, engineered macrophages, cancer treatment, solid tumors, chimeric antigen receptor technology, immunotherapy, clinical stage, novel technology, adoptive cell transfer, tumor micro-environment, solid tumor patients, clinical research, oncology, cancer therapy

Funding Rounds & Investors of Carisma Therapeutics (7)

View All
Funding Stage Amount No. Investors Investors Date
Series C $30.00M 10
HealthCap, investor in Carisma Therapeutics's Series C round Wellington Partners, investor in Carisma Therapeutics's Series C round Agent Capital, investor in Carisma Therapeutics's Series C round MRL Ventures Fund, investor in Carisma Therapeutics's Series C round Solasta Ventures, investor in Carisma Therapeutics's Series C round Symbiosis LLC, investor in Carisma Therapeutics's Series C round
TPG Biotech, Pictet Alternative Advisors +2 		21 Sep 2022
Series B $12.00M 10
HealthCap, investor in Carisma Therapeutics's Series B round IP Group, investor in Carisma Therapeutics's Series B round Wellington Partners, investor in Carisma Therapeutics's Series B round MRL Ventures Fund, investor in Carisma Therapeutics's Series B round Solasta Ventures, investor in Carisma Therapeutics's Series B round Symbiosis LLC, investor in Carisma Therapeutics's Series B round The Leukemia & Lymphoma Society, investor in Carisma Therapeutics's Series B round
TPG Biotech, Penn Medicine Co-Investment Program +1 		01 Mar 2021
Series B $47.00M 10
HealthCap, investor in Carisma Therapeutics's Series B round IP Group, investor in Carisma Therapeutics's Series B round Wellington Partners, investor in Carisma Therapeutics's Series B round AbbVie Ventures, investor in Carisma Therapeutics's Series B round Agent Capital, investor in Carisma Therapeutics's Series B round MRL Ventures Fund, investor in Carisma Therapeutics's Series B round Solasta Ventures, investor in Carisma Therapeutics's Series B round Symbiosis LLC, investor in Carisma Therapeutics's Series B round
TPG Biotech, Livzon Pharmaceutical Group 		07 Jan 2021
Series A $6.00M 2
HealthCap, investor in Carisma Therapeutics's Series A round AbbVie Ventures, investor in Carisma Therapeutics's Series A round
08 Aug 2019
Series A $53.00M 9
HealthCap, investor in Carisma Therapeutics's Series A round IP Group, investor in Carisma Therapeutics's Series A round Wellington Partners, investor in Carisma Therapeutics's Series A round AbbVie Ventures, investor in Carisma Therapeutics's Series A round Agent Capital, investor in Carisma Therapeutics's Series A round Grazia Equity, investor in Carisma Therapeutics's Series A round MRL Ventures Fund, investor in Carisma Therapeutics's Series A round
TPG Biotech, Penn Medicine Co-Investment Program 		27 Jun 2018

View All 7 Funding Rounds

Latest News of Carisma Therapeutics

View All

No recent news or press coverage available for Carisma Therapeutics.

Similar Companies to Carisma Therapeutics

View All
Nkarta, Inc. - Similar company to Carisma Therapeutics
Nkarta, Inc. Harnessing the Power of Natural Killer Cells
Huasaiboman Medical Cell Biology - Similar company to Carisma Therapeutics
Huasaiboman Medical Cell Biology Pioneering tomorrow's treatments for solid tumors and degenerative diseases through state-of-the-art cell therapy solutions.
Iovance Biotherapeutics, Inc. - Similar company to Carisma Therapeutics
Iovance Biotherapeutics, Inc. Iovance is a patient-centric, collaborative organization that is driven to change the way cancer is treated.
Cell BioEngines, Inc - Similar company to Carisma Therapeutics
Cell BioEngines, Inc ‘Off-the-Shelf’ Curative Cell Therapies
Grit Biotechnology - Similar company to Carisma Therapeutics
Grit Biotechnology Developing novel cell therapies to transform the lives of people with cancer.
Circle Decoration Circle Decoration

Want to dive deeper into Carisma Therapeutics? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now